Neurogene Inc. (NGNE) News
Follow Neurogene Inc. (NGNE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Neurogene Reports $29.0 Million Third-Quarter Net Loss
Neurogene reported a $29.0 million net loss for the third quarter of 2026, versus $21.0 million a year earlier. Cash, cash equivalents and short-term investments totaled $359.7 million at quarter-end; the headline says c
EQUITY | Nov 09, 2026, 01:23 PM UTC
M
Neurogene Reports Third-Quarter 2026 Financial Results and Recent Updates
Neurogene announced its third-quarter 2026 financial results and highlighted recent corporate updates.
EQUITY | Nov 09, 2026, 12:30 PM UTC
L
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of
EQUITY | Nov 05, 2026, 09:01 PM UTC
L
Neurogene to participate in H.C. Wainwright 28th conference
Neurogene management will participate in the H.C. Wainwright 28th Annual Global Investment Conference, the company said.
EQUITY | Sep 08, 2026, 11:30 AM UTC
L
Neurogene board panel approves Nasdaq Rule 5635 inducement stock option grants
Neurogene said its Compensation Committee approved non-qualified stock option inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:01 PM UTC
L
Neurogene shares are trading lower after the company announced a proposed public offering.
Neurogene shares are trading lower after the company announced a proposed public offering.
EQUITY | Jun 30, 2026, 08:04 PM UTC
L
Neurogene Reveals Proposed Public Offering; No Size Disclosed
Neurogene Inc. (NASDAQ: NGNE ), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has commenced a public of
EQUITY | Jun 30, 2026, 08:02 PM UTC